PureTech Health plc American Depositary Shares (PRTC)

Price$17.25

Value ScoreC

Growth ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-7.45%

Price vs S&P 500 (4W)-0.78%

VGM Score40.49

Market Capitalization$308.17M

P/E Ratio (Annual)7.87x

All Metrics

Book Value / Share (Quarterly)$1.29

P/TBV (Annual)1.31x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-33.18%

Cash Flow / Share (Quarterly)$-0.35

Price vs S&P 500 (YTD)-7.20%

Net Profit Margin (TTM)-2355.44%

EPS (TTM)$-0.46

10-Day Avg Trading Volume0.37M

EPS Excl Extra (TTM)$-0.46

Revenue Growth (5Y)-16.92%

EPS (Annual)$-0.46

ROI (Annual)-33.09%

Net Profit Margin (5Y Avg)-778.13%

Cash / Share (Quarterly)$1.20

P/E Basic Excl Extra (TTM)8.31x

Revenue Growth QoQ (YoY)-38.15%

EPS Growth (5Y)-32.45%

P/E Normalized (Annual)7.87x

ROA (Last FY)-20.52%

Revenue Growth TTM (YoY)-3.50%

EBITD / Share (TTM)$-0.39

ROE (5Y Avg)-11.18%

Operating Margin (TTM)-2078.30%

Cash Flow / Share (Annual)$-0.35

P/B Ratio1.32x

P/B Ratio (Quarterly)1.31x

Net Income / Employee (Annual)$-1,799,000

EV / Revenue (TTM)38.25x

Net Interest Coverage (TTM)-0.15x

ROA (TTM)-20.17%

EV / EBITDA (TTM)4.62x

EPS Incl Extra (Annual)$-0.46

Current Ratio (Annual)6.59x

Quick Ratio (Quarterly)6.44x

3-Month Avg Trading Volume0.30M

52-Week Price Return-9.73%

P/E Incl Extra (TTM)8.31x

Revenue / Employee (TTM)$76,400

Tangible BV / Share (Quarterly)$1.29

P/S Ratio (Annual)88.24x

Asset Turnover (Annual)0.01x

52-Week High$148.00

Operating Margin (5Y Avg)-1222.57%

EPS Excl Extra (Annual)$-0.46

CapEx CAGR (5Y)-74.37%

Tangible BV CAGR (5Y)-14.18%

26-Week Price Return0.48%

Quick Ratio (Annual)6.44x

13-Week Price Return2.10%

Total Debt / Equity (Annual)0.06x

Current Ratio (Quarterly)6.59x

Enterprise Value$178.23M

Revenue / Share Growth (5Y)-13.65%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-11.23%

Revenue / Employee (Annual)$76,400

Pretax Margin (Annual)-2380.92%

Cash / Share (Annual)$1.20

3-Month Return Std Dev43.74%

Net Income / Employee (TTM)$-1,799,000

EBITDA CAGR (5Y)-55.29%

ROE (Last FY)-35.16%

Net Interest Coverage (Annual)-0.15x

EPS Basic Excl Extra (Annual)$-0.46

Receivables Turnover (TTM)2.84x

Total Debt / Equity (Quarterly)0.06x

EPS Incl Extra (TTM)$-0.46

Receivables Turnover (Annual)2.84x

ROI (TTM)-30.13%

P/S Ratio (TTM)88.24x

Pretax Margin (5Y Avg)-781.15%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$1.29

Price vs S&P 500 (52W)-34.09%

P/E Ratio (TTM)8.31x

Year-to-Date Return0.96%

5-Day Price Return-5.26%

EPS Normalized (Annual)$-0.46

ROA (5Y Avg)-6.94%

Net Profit Margin (Annual)-2355.44%

Month-to-Date Return-9.08%

Cash Flow / Share (TTM)$-0.09

EBITD / Share (Annual)$-0.39

Operating Margin (Annual)-2078.30%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-10.44%

P/E Excl Extra (TTM)8.31x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.46

P/TBV (Quarterly)1.31x

P/B Ratio (Annual)1.31x

Pretax Margin (TTM)-2380.92%

Book Value / Share (Annual)$1.29

Price vs S&P 500 (13W)-6.15%

Net Margin Growth (5Y)-23.72%

Beta1.27x

Revenue / Share (TTM)$0.02

ROE (TTM)-31.90%

52-Week Low$104.80

vGradeC

gGradeF

mGradeC

vgmGradeC

Show chart for

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.20

4.17

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
PRTCPureTech Health plc American Depositary Shares	C	F	C	$17.25
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

PureTech Health is a clinical-stage biopharmaceutical company developing medicines for inflammatory, immunological, neurological, and gastrointestinal disorders, as well as intractable cancers. Key pipeline assets include Deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis and SPT-300, an oral therapy for depressive disorder.